Henlez develops a transformative platform therapeutic based on enzyme technology to treat some of the most physically and mentally disabling skin diseases in the world.

Henlez was founded by two former Novozymes employees Jeppe Christian Mouritsen and Rikke Nørregaard-Sarup. To realise their idea, they secured a mutually beneficial partnership and technology spin-out deal with Novozymes.
Henlez’s mission is not only to develop a new type of drug, but also on contributing to the public understanding of pathogenesis through collaborations. It is a key focus to Henlez to understand patient perspectives in detail, their problems, practical everyday and longterm challenges – in short working from the get go to map the detailed unmet need. The point is to develop a drug that is on one hand effective and safe, but on the other also affordable and user friendly.

Skin disease, enzyme, drug, therapeutics
Between €100K-€500K
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as Henlez? We’re happy to assist you with our Startup Sourcing service.